Goodpasture syndrome is a rare autoimmune disorder characterized by the presence of autoantibodies that attack the kidneys and lungs. It was first described by Ernest Goodpasture in 1919. The syndrome primarily affects young adults, with a peak incidence between the ages of 20 and 30.
The prevalence of Goodpasture syndrome is relatively low, estimated to be around 1 in 1 million individuals. Although it is considered rare, it is important to note that prevalence rates may vary across different populations and regions.
Goodpasture syndrome can have severe consequences if left untreated. The autoantibodies target the basement membrane of the kidneys and lungs, leading to glomerulonephritis and pulmonary hemorrhage. Prompt diagnosis and treatment are crucial to prevent irreversible damage to these organs.
Treatment typically involves a combination of immunosuppressive medications and plasma exchange therapy to remove the harmful autoantibodies. With early intervention, the prognosis for Goodpasture syndrome has improved over the years, but it remains a serious condition requiring ongoing medical management.